Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “sector perform” rating reissued by equities research analysts at Royal Bank of Canada in a research note issued to investors on Thursday. They presently have a $425.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $473.00. Royal Bank of Canada’s price target would indicate a potential upside of 5.06% from the company’s previous close.
A number of other research analysts also recently commented on the company. Barclays PLC downgraded Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $490.00 target price (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $484.00 target price (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $557.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $481.49.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $1.67 on Thursday, reaching $404.54. The company had a trading volume of 771,100 shares, compared to its average volume of 900,360. The stock has a market capitalization of $43,525.81, a P/E ratio of 35.17, a P/E/G ratio of 1.40 and a beta of 1.56. Regeneron Pharmaceuticals has a 1 year low of $340.09 and a 1 year high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.21.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter last year, the business posted $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. sell-side analysts anticipate that Regeneron Pharmaceuticals will post 13.77 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Reaffirmed by Royal Bank of Canada” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/regeneron-pharmaceuticals-inc-regn-stock-rating-reaffirmed-by-royal-bank-of-canada.html.
In related news, Chairman P Roy Vagelos sold 10,986 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total value of $5,165,287.62. Following the transaction, the chairman now directly owns 329,543 shares in the company, valued at approximately $154,941,232.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 88,942 shares of company stock worth $42,064,076. 10.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after acquiring an additional 416,192 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after acquiring an additional 41,406 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Regeneron Pharmaceuticals by 1.5% in the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares during the period. Finally, Polen Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.3% in the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock worth $779,105,000 after buying an additional 108,413 shares during the period. Institutional investors and hedge funds own 67.63% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.